CagriSema is a fixed-dose combination of cagrilintide and semaglutide being studied as a more potent obesity therapy than either alone.

Cagrilintide Calculator

Also known as: AM833

GLP-1

Default: 9mg / 2mL / 0.6mgAdjust inputs to match your vial

About

What is Cagrilintide?

Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk, often combined with semaglutide as CagriSema. Amylin agonists modulate satiety and gastric emptying through mechanisms distinct from GLP-1 agonism. Trial protocols use weekly titration from 0.3 mg up to 2.4 mg or higher.

Common vial sizes

4.5 mg	lyophilized powder
9 mg	lyophilized powder

Reference dose ranges

0.3 mg	≈ 6.7 U-100 units (at 9mg / 2mL)
0.6 mg	≈ 13.3 U-100 units (at 9mg / 2mL)
1.2 mg	≈ 26.7 U-100 units (at 9mg / 2mL)
2.4 mg	≈ 53.3 U-100 units (at 9mg / 2mL)
4.5 mg	≈ 100 U-100 units (at 9mg / 2mL)

Reconstitution

How it's typically prepared

Reconstitute with BAC water and store refrigerated. Compounded cagrilintide vial sizes vary by pharmacy.

FAQ

Frequently asked questions

What is CagriSema?: CagriSema is a fixed-dose combination of cagrilintide and semaglutide being studied as a more potent obesity therapy than either alone.

Sources

References

Other GLP-1 peptides

Notice

PeptideDose is an educational reference. It is not medical advice and does not replace consultation with a licensed healthcare provider. Doses shown in presets are derived from published protocols and product labels — they are not personal recommendations.